Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Balzarotti

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Haematologica|July 22, 2021
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcomeAnna Dodero, Anna Guidetti, Fabrizio Marino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2011
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trialUmberto Vitolo, Annalisa Chiappella, Andrés J M Ferreri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 StudyMaurizio Martelli, Luca Ceriani, Emanuele Zucca, et al.
Hematological Oncology|February 7, 2019
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical networkSara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, et al.
Leukemia & Lymphoma|February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
The Oncologist|April 4, 2019
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical PracticeAlessandro Broccoli, Beatrice Casadei, Annalisa Chiappella, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Annals of Hematology|July 30, 2021
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana LinfomiArmando Santoro, Rita Mazza, Michele Spina, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Hematological Oncology|May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana LinfomiStefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Haematologica|July 22, 2021
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcomeAnna Dodero, Anna Guidetti, Fabrizio Marino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2011
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trialUmberto Vitolo, Annalisa Chiappella, Andrés J M Ferreri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 StudyMaurizio Martelli, Luca Ceriani, Emanuele Zucca, et al.
Hematological Oncology|February 7, 2019
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical networkSara Rattotti, Virginia Valeria Ferretti, Chiara Rusconi, et al.
Leukemia & Lymphoma|February 17, 2016
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, et al.
The Oncologist|April 4, 2019
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical PracticeAlessandro Broccoli, Beatrice Casadei, Annalisa Chiappella, et al.
British Journal of Haematology|February 3, 2023
Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana LinfomiAnnalisa Arcari, Valentina Tabanelli, Francesco Merli, et al.
The Lancet. Oncology|July 3, 2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 studyAnnalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, et al.
Annals of Hematology|July 30, 2021
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana LinfomiArmando Santoro, Rita Mazza, Michele Spina, et al.
Pageof 8